Financing ·
Cardiol Therapeutics received over USD $7 million in proceeds from the exercise of outstanding common share purchase…
CRDLCardiol Therapeutics Inc.
Cardiol Therapeutics received over USD $7 million in proceeds from the exercise of outstanding common share purchase warrants, strengthening its balance sheet and extending its cash runway into the first half of 2028. The capital will fund operations through topline data readout from the pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis and support regulatory preparations for a potential New Drug Application. As of September 15, 2026, 425,000 warrants remained unexercised out of an original issuance of 5,712,500, representing additional potential gross proceeds of USD $573,750. The company exercised its Acceleration Right, causing the remaining warrants to expire at 4:00 p.m. Eastern Time on October 16, 2026, with any unexercised warrants automatically cancelled for no consideration. Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease.